Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


The hetero ring has exactly 13 ring carbons (e.g., erythromycin, etc.)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514023000 - Carbohydrate (i.e., saccharide radical containing) DOAI

514025000 - O-glycoside

514027000 - Oxygen of the saccharide radical bonded directly to a nonsaccharide hetero ring or a polycyclo ring system which contains a nonsaccharide hetero ring

514028000 - The hetero ring has 8 or more ring carbons

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20130045938KINASE MODULATORS FOR THE TREATMENT OF CANCER - A method of treating cancer in which a compound that inhibits the expression, production or release of IL-10 by immune cells is combined with a compound that stimulates the production of IL-12 when given in combination with, or in the presence of TNFa. Said method is effective when provided in addition to standard therapies, notably chemotherapy using cytotoxic drugs and other forms of immune therapy including therapeutic vaccines.02-21-2013
20130045939FATTY ACID MACROLIDE DERIVATIVES AND THEIR USES - The invention relates to fatty and macrolide derivatives; compositions comprising an effective amount of fatty acid macrolide derivative; and methods for treating or preventing an autoimmune disorders and diseases with inflammation as the underlying etiology comprising the administration of an effective amount of a fatty acid macrolide derivative.02-21-2013
20130045937PARENTERAL FORMULATIONS OF MACROLIDE ANTIBIOTICS - Described herein are pharmaceutical compositions adapted for the parenteral administration of macrolide antibiotics, such as triazole-containing and fluoroketolide antibiotics. Also described herein are methods for their use in the treatment of bacterial, protozoal, and other infections.02-21-2013
20130045936COMPOSITION COMPRISING AN AMORPHOUS NON-CRYSTALLINE GLASS FORM OF ROXITHROMYCIN - The invention relates to an amorphous non-crystalline glass form (Form-ll) of 3R,4S,5S,6R,7R,9R,11S,12R,13S,14R-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-1-oxa-cyclotetradecan-2-one or roxithromycin having at least one characteristic infra-red spectrum peak at approximately 3580 to 3464 cm02-21-2013
20120172323METHODS FOR TREATING MALARIA, TUBERCULOSIS AND MAC DISEASES - Described herein are formulations and methods for treating diseases caused by infectious pathogens, including 07-05-2012
20100075913Pharmaceutical anti-infective composition for inhalation - A composition for inhalation which contains at least an effective amount of an antimicrobial aminoglycoside compound or a salt thereof, and an effective amount of a biofilm modifier which is a macrolide compound or a salt thereof.03-25-2010
20090124563ORAL EXTENDED-RELEASE COMPOSITION - The invention is directed to controlled release formulations containing drugs which are preferably considered sparingly soluble to insoluble and which are suitable for administration to a patient in need of treatment related thereto, and methods of manufacturing the same.05-14-2009
20130059805COMPOSITION COMPRISING AN AMORPHOUS NON-CRYSTALLINE GLASS FORM OF AZITHROMYCIN - The invention relates to an amorphous non-crystalline glass form (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadec-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranoside or azithromycin having an infra-red pattern displaying characteristic relatively broad peaks at approximately 3500 and 1727 cm03-07-2013
20130065845Triazole Compounds and Methods of Making and Using the Same - The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.03-14-2013
20110028418USE OF GABBA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXCESSIVE SLEEPINESS AND DISORDERS ASSOCIATED WITH EXCESSIVE SLEEPINESS02-03-2011
20090093420PROCESSES FOR THE PREPARATION OF AZITHROMYCIN - The invention relates to processes for the preparation of anhydrous azithromycin. The invention also relates to a one-pot process for the preparation of azithromycin without isolation of intermediates. The invention also relates to pharmaceutical compositions that include the anhydrous azithromycin or a pharmaceutically acceptable salt thereof.04-09-2009
20110281812Compounds - 2′-O-substituted 14- or 15-membered azalide macrolides of Formula (I)11-17-2011
20100197621METHODS OF REDUCING THE PROLIFERATION AND VIABILITY OF MICROBIAL AGENTS - The invention relates to formulations of an antimicrobial agent, a lipid, and optionally a surfactant, and uses thereof for reducing the proliferation and viability of microbial agents.08-05-2010
20110281811Use Of Leukotriene Inhibitors For Treating Lung Diseases In Prematurely Born Infants - The invention relates to the use of at least one leukotriene inhibitor for preparing a pharmaceutical composition for the prophylaxis and/or treatment of lung diseases, more particularly of bronchopulmonary dysplasia, in prematurely born infants. The invention further relates to a pharmaceutical composition for the prophylaxis and/or treatment of lung diseases, more particularly of bronchopulmonary dysplasia, in prematurely born infants, the pharmaceutical composition comprising at least one leukotriene inhibitor. The invention additionally relates to a method for the treatment and/or prophylaxis of a lung disease, more particularly of a bronchopulmonary dysplasia, in a prematurely born infant, where the prematurely born infant is administered a pharmacologically active amount of at least one leukotriene inhibitor.11-17-2011
20110281810Composition - The present invention relates to the use of a solubilizer for enhancing the solubility of an active pharmaceutical ingredient in water. The present invention further relates to a composition comprising a solubilizer and at least one active pharmaceutical ingredient. In both cases the solubilizer is an alkoxylated monoalcohol or a mixture of alkoxylated monoalcohols, where the alkoxylated monoalcohol or, if a mixture of alkoxylated monoalcohols is present, at least one alkoxylated monoalcohol in the mixture comprises at least one oxypropylene unit.11-17-2011
20090005326SINGLE DOSE ROXITHROMYCIN - The invention relates to a method of treating a bacterial infection in an animal by administering a single dose of roxithromycin.01-01-2009
20110105421ELLAGITANNINS AS INHIBITORS OF BACTERIAL QUORUM SENSING - Described herein are materials and methods for the inhibition of bacterial QS. Methods of treating bacterial infections by administration of one or more ellagitannins in amount effective to inhibit bacterial QS is also provided.05-05-2011
20110288040ARYL- OR HETEROARYL-SULFONYL COMPOUNDS AS ACID SECRETION INHIBITORS - The present invention provides a compound having a superior acid secretion inhibitory action, an antiulcer activity and the like.11-24-2011
20100197622Non-Peptide Macrocyclic Histone Deacetylase (HDAC) Inhibitors and Methods of Making and Using Thereof - Compounds of Formula I or II, and methods of making and using thereof, are described herein.08-05-2010
20080312168Novel Dispersible Tablet Composition - The present invention relates to a novel dispersible tablet composition, which comprises of a pharmacologically active ingredient and at least one excipient, which reduces the sedimentation rate of active ingredient. This invention further relates to a process for the preparation of a dispersible tablet of a pharmacologically active ingredient.12-18-2008
20100099635METHOD FOR TREATING CYSTIC FIBROSIS - The present invention is directed to a method for treating cystic fibrosis. The method comprises the steps of: identifying a patient suffering from cystic fibrosis, and administering to the patient an effective amount of denufosol or a pharmaceutically acceptable salt thereof and an effective amount of a macrolide. In one method, denufosol and the macrolide are administered by inhalation, preferably in a single formulation. In another method, denufosol is administered by inhalation and the macrolide is administered orally. The present invention is also directed to a pharmaceutical formulation comprising denufosol or a pharmaceutically acceptable salt thereof, a macrolide, and a pharmaceutically acceptable carrier. Preferred denufosol is denufosol tetrasodium and preferred macrolide is azithromycin. The pharmaceutical formulation preferably is in a form of an inhalable dry powder or in a liquid form.04-22-2010
20100113376PROCESS FOR DOSING SELF-EMULSIFYING DRUG DELIVERY SYSTEMS - The present invention provides process for dosing a self-dispersing drug delivery system comprising an active compound, said process comprising the step of using a dosage dispenser to dose a defined amount of said self-dispersing drug delivery system comprising an active compound and a dosage dispenser containing a self-dispersing drug delivery system comprising an active compound.05-06-2010
20090062220DEUTERIUM-ENRICHED AZITHROMYCIN - The present application describes deuterium-enriched azithromycin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-05-2009
200901493986,11-3c-bicyclic 8a-azalide derivatives - Compounds of Formula (I), and pharmaceutically acceptable salts, esters, and prodrugs thereof: (I) are disclosed, wherein A, B, D, L, X, Y, Z and R06-11-2009
20090018090PROCESS FOR PREPARATION OF ANHYDROUS AZITHROMYCIN - The present invention provides a stable form of azithromycin derivatives that act as antibiotics. These compounds are in anhydrous form and have increased stability over the hydrated forms.01-15-2009
20110245190METHOD FOR IMPROVING POST SURGERY VISUAL ACUITY OUTCOME WITH AZITHROMYCIN - The present invention relates to a method for treating dry eye disease, comprising the steps of identifying a subject suffering from dry eye disease, and administering to the subject an effective amount of azithromycin. The present invention also relates to a method for reducing contact lens intolerance in a subject, comprising the steps of: identifying a subject suffering from contact lens intolerance due to dry eye disease; and administering to the eyes of the subject an aqueous ophthalmic solution comprising azithromycin. The present invention also relates to a method for improving post surgery visual acuity outcome in a patient, comprising the steps of: identifying a patient in need of an ophthalmic surgical procedure, administering to the patient an effective amount of azithromycin prior to the ophthalmic surgical procedure, and performing the ophthalmic surgical procedures on the patient.10-06-2011
20120035121ANTIBIOTIC PRODUCT, USE AND FORMULATION THEREOF - An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the C02-09-2012
20100120706Macrolides Useful Against Inflammatory and Allergic Diseases - Macrolide compounds of formula I: with PDF4 inhibiting activity are described, wherein R1 is a residue —Y—X-Q; Y is S, SO or SO05-13-2010
20100099634MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY - The present invention relates to macrolide derivatives of formula (I) in which R04-22-2010
20110201566METHODS FOR TREATING RESISTANT DISEASES USING TRIAZOLE CONTAINING MACROLIDES - Triazole-containing macrolide and ketolide antibiotics, therapeutic compositions containing them and methods of use for treating diseases caused by one or more resistant organisms are described.08-18-2011
20090088395CLARITHROMYCIN OR SALT THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF PULMONARY DISEASE INDUCED BY DESTRUCTION OF PULMONARY ALVEOLI - For the purpose of treatment and/or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli resulting from smoking, air pollution, noxious gas, etc., there are provided, among others, a method of administering clarithromycin or a salt thereof to a mammal and a pharmaceutical composition comprising clarithromycin or a salt thereof.04-02-2009
20090281050ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES - The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof:11-12-2009
20090042814Treatment and Diagnosis of Obligate Intracellular Pathogens - This invention relates to the detection of pathogens, in particular persistent forms of obligate intracellular or membrane associated microorganisms such as 02-12-2009
20130217641COMPOSITIONS FOR TREATING HELICOBACTER PYLORI INFECTION - Pharmaceutical compositions for treating infection from 08-22-2013
20090036388Compounds - The present invention relates to novel 2′-O-substituted 9-deoxo-902-05-2009
20080207536Antibacterial Agents - The present invention provides acylide derivatives, which can be used as antibacterial agents. Compounds disclosed herein can be used for the treatment or prevention of a condition caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against bacterium such as 08-28-2008
20080221048Lyophilized azithromycin formulation - The invention provides among other things a stable, sterile pharmaceutical formulation comprising lyophilized azithromycin and ethanol. The invention also provides a method of producing a stable, sterile pharmaceutical product comprising lyophilized azithromycin. The invention also provides a pharmaceutical dosage form comprising the pharmaceutical formulation, as well as a method of treating a disease in a patient comprising administering a solution of the pharmaceutical formulation to a patient.09-11-2008
200902643806,11-BRIDGED BIARYL MACROLIDES - The present invention discloses compounds of formula I, II or X, or pharmaceutically acceptable salts, esters, or prodrugs thereof:10-22-2009
20110269704METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY - A liquid pharmaceutical composition to be applied to the skin as a foam and that has at least one solvent, at least one active pharmaceutical ingredient, and at least one foaming agent. The foam volume and the foam stability are determined according to a standardized SITA measuring method. The foaming agent, the solvent, and the active pharmaceutical ingredient are varied in regard to the chemical type and/or concentration thereof until the foam thus produced by the SITA measuring method has a foam volume of at least 400 ml and such foam stability that after a dwell time of up to ten minutes the foam still has at least 50% of the foam volume that originally existed immediately after the foam was produced.11-03-2011
20080318878Antibacterial Agents - The present invention provides acylide derivatives, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, 12-25-2008
20090005325Ketolide Derivatives as Antibacterial Agents - Provided herein are ketolide derivatives, which can be used as antibacterial agents. Compounds described herein can be used for treating or preventing conditions caused by or contributed to by gram positive, gram negative or anaerobic bacteria, more particularly against, for example, 01-01-2009
20090062221Azithromycin for treatment of skin disorders - Azithromycin has increased efficacy in treating acne and other skin conditions when administered systemically at low doses, below those previously known to produce a clinical antibiotic effect.03-05-2009
20090062219DRUGS FOR THE TREATMENT AND/OR PROPHYLAXIS OF GASTROPARESIS SYMPTOM - The present invention provides a therapeutic and/or preventive agent against gastroparesis symptom which is appropriate for continuous medication and which comprises a compound represented by formula (1):03-05-2009
20090054357MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY - Macrolide compounds endowed with antiinflammatory activity are described, and more particularly macrolide derivatives lacking cladinose in position 3, with antiinflammatory activity, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as active ingredient.02-26-2009
20080287376Ketolide Derivatives as Antibacterial Agents - The present invention provides ketolide derivatives, which can be used as antibacterial agents. In particular, compounds described herein can be used for treating or preventing conditions caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, 11-20-2008
20090197822Compositions and Methods for the Treatment of Chronic Infections - The present disclosure provides compositions and methods for the treatment and elimination of chronic intracellular infections in cells or organisms. The compositions may include one or more acidic substances and one or more antimicrobial substances, administered in combination or separately. The methods may include administering an amount of one or more such compositions to an infected cell or organism for a period of time ranging from days to years, until the infection is substantially eliminated.08-06-2009
20090221518Compositions and Methods for Treatment of Exudative Serous Effusion - Compositions and methods are provided for treating accumulation of exudative serous effusions caused by illnesses such as cancer, infection, and pancreatitis. In one embodiment, the method of the invention comprises administering to such mammal a macrolide in an amount effective to prevent or at least alleviate said exudative serous effusion accumulation.09-03-2009
20090247478Novel macrolides and ketolides having antimicrobial activity - The present invention provides compounds having antimicrobial activity for preventing and treating diseases caused by microbial infections. Thus, the present invention relates to novel semi-synthetic 11,12-γ lactone macrolides and ketolides having antimicrobial activity, processes for making compounds as well as pharmaceutical compositions containing said compounds as active ingredients and methods of treating microbial infections with the compounds.10-01-2009
20100216732Azithromycin for the treatment of nodular acne - Azithromycin, administered systemically, is an effective treatment for nodules associated with acne vulgaris.08-26-2010
20100222289METHODS FOR DIAGNOSIS AND TREATMENT OF CHRONIC FATIGUE SYNDROME - Methods for diagnosing and treating chronic fatigue syndrome in a patient comprise, for example, testing tissue of the patient for the presence of nucleic acid molecules of one or more CFS-causing herpesviruses and one or more non-herpesvirus infectious agents, and diagnosing the patient's CFS as (a) caused by one or more herpesvirus and no non-herpesvirus infectious agent; (b) caused by one or more herpesviruses and at least one non-herpesvirus infectious agent; (c) not caused by a herpesvirus and caused by at least one non-herpesvirus infectious agent; and (d) not caused by a herpesvirus and not caused by at least one non-herpesvirus infectious agent. In some embodiments, the methods of treating comprise administering a therapeutically effective amount of at least one pharmaceutical composition for each herpesvirus and/or non-herpesvirus infectious agent present found in the patient.09-02-2010
20090075917DEUTERIUM-ENRICHED TELITHROMYCIN - The present application describes deuterium-enriched telithromycin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20090075916Use of Macrolide Derivatives for Treating Acne - This invention relates to 14-membered macrolide derivatives for treating or preventing acne vulgaris and associated inflammatory conditions. Also provided herein are medicaments or pharmaceutical compositions comprising one or more 14-membered macrolide derivatives together with one or more pharmaceutically acceptable carriers, excipients, diluents or mixture thereof, and methods for treating or preventing acne vulgaris and associated inflammatory conditions.03-19-2009
200802691464''-Substituted Erythromycin Derivative - A compound of formula (I)10-30-2008
20090221519COMBINATIONS OF RECEPTOR TYROSINE KINASE INHIBITOR WITH AN A1-ACIDIC GLYCOPROTEIN BINDING COMPOUND - This invention relates to combinations of an abl-, PDGF-Receptor- and/or Kit receptor-tyrosine kinase inhibitor with an organic compound capable of binding to α09-03-2009
20090111760MACROLONE COMPOUNDS - A compound of formula (I)04-30-2009
20100305054CONCENTRATED AQUEOUS AZALIDE FORMULATIONS - The present invention relates to formulations of concentrated azalide antibiotics and methods for making and using them. Specifically, the invention relates to a method of treating an infection comprising administering to a patient in need thereof, an effective amount of a concentrated aqueous azalide antibiotic formulation made according to the method comprising dissolving an azalide antibiotic in an aqueous solution comprising a strong acid. The invention also relates to methods for making concentrated aqueous azalide antibiotic formulations for use in pulmonary infection, a nasopharyngeal infection, an otic infection, an ocular infection, a dermal or a vaginal infection. The invention also relates to concentrated aqueous azalide antibiotic formulations made by dissolving an azalide antibiotic in an aqueous solution comprising a strong acid.12-02-2010
20090069255DEUTERIUM-ENRICHED CLARITHROMYCIN - The present application describes deuterium-enriched clarithromycin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-12-2009
20100222290Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics - Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.09-02-2010
20110028417Macrocyclic Compounds and Methods of Use Thereof - The invention features novel macrocyclic compounds, methods of making the compounds, pharmaceutical compositions including the compounds, and methods of treatment using the compounds.02-03-2011
201100397952'-O,3'-N-BRIDGED MACROLIDES - Novel 2′-O,3′-N-bridged macrolides useful in treatment of inflammatory diseases. More particularly, the invention relates to 2′-O,3′-N-bridged 14-membered macrolides and to 2′-O,3′-N-bridged 15-membered azalide macrolides useful in treatment of neutrophil dominated inflammatory diseases resulting from neutrophilic infiltration and/or diseases associated with altered cellular functionality of neutrophils, to intermediates for their preparation, to the methods for their preparation, to their use as therapeutic agents, and to salts thereof.02-17-2011
20100216731PROCESS FOR THE PREPARATION OF MACROLIDE ANTIBACTERIAL AGENTS - Described herein are processes for the preparation of compounds of formula (I): and pharmaceutically acceptable salts, solvates, and hydrates thereof.08-26-2010
20100197623Anti-Infammatory Macrolide - The compound 3′-N-demethyl-4″-O-(2-diethylaminoethanoyl)-6-O-methyl-9a-aza-9a-homoerythromycin A, having the Formula (I):08-05-2010
20100069315METHOD AND MEDICAMENT FOR TREATING OCULAR INFECTIONS - The invention relates to a method for treating ocular infections, by topical application twice a day in each eye to be treated, for less than four days, of a medicament essentially consisting of azithromycin in solution in a pharmaceutically acceptable vehicle of linear medium-chain fatty acid triglycerides, at the concentration of 1% to 2%.03-18-2010
20080249034Use of Macrolides for Treating Intestinal Inflammation - The present invention relates to a compound of formula (IA) as defined in the specification or a pharmaceutically acceptable sat thereof, in the preparation of a medicament for both the treatment of inflammatory bowel diseases and the prevention of colon cancer.10-09-2008
20090131342Nitrosated and/or nitrosylated compounds, compositions and methods of use - The invention describes novel nitrosated and/or nitrosylated compounds of the invention and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, and at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. The nitrosated and/or nitrosylated compounds of the invention are preferably nitrosated and/or nitrosylated antimicrobial compounds, nitrosated and/or nitrosylated adenosine antagonists, nitrosated and/or nitrosylated LTB4 antagonists, nitrosated and/or nitrosylated mucoregulators and nitrosated and/or nitrosylated purine agonists. The methods of the invention are preferably for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis.05-21-2009
20100004189COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS - Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating cystic fibrosis or a symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered fluids optionally in combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). Particular embodiments comprise use and/or synergy with tobramycin for treating bacterial infection, and use and/or synergy with a bronchiodilator. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (like, membrane receptors, including but not limited to G protein coupled receptors, and intercellular junctions).01-07-2010
20080255060Ester Linked Macrolides Useful For The Treatment of Microbial Infections - The present invention relates to 14- or 15-membered macrolides substituted at the 4″ position of formula (I)10-16-2008
20110021449MACROLIDES AND USES OF MACROLIDES - Macrolides of Formula (I) or (I-A): and wherein the residues R1, R2, R3, R4, R12, R13 and R14 have certain meanings defined in this application are useful for treating or preventing inflammatory or allergic diseases or. cancer in animals and humans.01-27-2011
20110053876 MACROLIDES AND THEIR USE - The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with anti-inflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.03-03-2011
20100323978Non-aqueous oil delivery system for ophthalmic drugs - The present invention relates to a delivery system for ophthalmic drugs, and more particularly, to a non aqueous oil delivery system. Low concentrations of ophthalmic drugs suspended in an oil vehicle delivery system are as therapeutically effective in man and animals as the corresponding higher concentrations of ophthalmic drugs that are commercially used in aqueous solutions. Eye drops that utilize this nonaqueous oil delivery system, when used in man, are comfortable to use and produce little ocular irritation, have a longer shelf-life, low systemic toxic potential, and only short term blurring of vision. Using this nonaqueous oil delivery system, a single drop of ophthalmic drug with a concentration that is 10 times less than the same drug used in commercially available aqueous eye drops is as effective as the commercially available aqueous ophthalmic eye drops that require many applications to be effective. In addition, utilizing the nonaqueous oil delivery system as eye drops produces no ocular sensation of burning, stinging or excessive tearing that is commonly associated with the commercially available aqueous eye drops. This very dilute ophthalmic drug preparation has a greatly reduced systemic toxicity potential as compared to the commercially used aqueous ophthalmic drops. The vehicle includes castor oil, corn oil, glycerol, mineral oil USP, vegetable oil, white petrolatum USP, and mixtures, there of. The ophthalmic class of drugs includes antimicrobials, miotics, mydriatics, mydriatic-cycloplegics, mydriatic-cycloplegic reversal agents and topical anesthetics.12-23-2010
20090176719COMPOSITIONS AND METHODS FOR TREATING PERIORAL DERMATITIS - Methods for treating perioral dermatitis are described herein. The method includes administering topically a composition containing an effective amount of a systemic or topical antibiotic and a corticosteroid. The concentration of the antibiotic is from about 0.01% to about 5% by weight of the composition and the concentration of the corticosteroid is from about 0.01% to about 5% by weight of the composition. The composition can contain one or more pharmaceutically acceptable excipients and/or carriers. The compositions can be formulated as a lotion, cream, gel, ointment, paste, powder, solution, suspension, spray, foam, or patch.07-09-2009
20100190734METHOD OF TREATING DRY EYE DISEASE WITH AZITHROMYCIN - The present invention relates to a method for treating dry eye disease. The method comprises identifying a subject suffering from dry eye disease, and administering to the subject an amount of azithromycin effective to reduce dry eye symptoms and/or signs ands to improve tear film quality. Azithromycin is preferably administered topically to the subject in an aqueous ophthalmic solution comprises 0.5-1.5% (w/v) azithromycin in a polymeric suspension.07-29-2010
20100022465METHOD OF TREATING BLEPHARITIS - The present invention relates to a method for treating non-infectious, inflammatory chronic posterior blepharitis in a subject. The present invention also relates to a method for treating chronic posterior blepharitis in a subject for over two weeks. The method comprises identifying a subject in need thereof, and topically administering to the eye of the subject a pharmaceutical formulation consisting essentially of an effective amount azithromycin. The present invention further relates to a method for treating dry eye secondary to blepharitis in a subject. The method comprises the steps of: identifying a subject suffering from dry eye secondary to posterior blepharitis, and topically administering to the eye of the subject a pharmaceutical formulation comprising an effective amount of azithromycin. The present invention further relates to method for reducing contact lens intolerance of a subject due to blepharitis or dry eye secondary to blepharitis.01-28-2010
20080287377Composition Based on Triethyl Citrate for the Prevention of Enzymatic Hydrolysis of Triglycerides - The invention concerns a composition for topical use for the protection of triglycerides against enzymatic hydrolysis, which contains triethyl citrate as an active ingredient either pure or in combination with some synergists. The triethyl citrate is in a quantity in weight expressed as a percentage from 0.1 to 99.9, preferably from 0.2 to 50 percent or even better a weight expressed as a percentage from 1.0 to 25.0. The claims are also directed to the use of triethylcitrate for the treatment of acne and seborrheic dermatitis, for the protection of triglycerides in alimentary products and for treatment of aesthetic cutaneous effects in the cosmic field.11-20-2008
20080293646MACROLIDES - The invention relates to compounds of Formula (I):11-27-2008
20110306571Methods for treating cancer - Use of a macrolide antibiotic for the manufacture of a medicament for the treatment or prevention of a cancer selected from colorectal cancer, Desmoid tumor, bladder cancer, gastric cancer, and breast cancer, the macrolide antibiotic being one or more of: tylosin, pharmaceutically acceptable salts thereof, and derivatives thereof; erythromycin, pharmaceutically acceptable salts thereof, and derivatives thereof; oleandomycin, pharmaceutically acceptable salts thereof, and derivatives thereof; and spiramycin, pharmaceutically acceptable salts thereof, and derivatives thereof. Also provided are pharmaceutical compositions and methods for the treatment or prevention of the above mentioned cancers and methods for treating or preventing, in a mammal, a cancer that expresses a mutated APC gene.12-15-2011
20090062218MACROLONE COMPOUNDS - A compound of formula (I)03-05-2009
20110172174Antibacterial agents - Antibacterial compounds of formula I are provided:07-14-2011
20120252747MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME - The present invention provides macrocyclic compounds useful as therapeutic agents of the formula:10-04-2012
20120115802Method for using ulipristal acetate with cytochrome isozyme modulators - The invention relates to a method of using ulipristal acetate or a metabolite thereof for providing contraception or for treating a patient's condition, comprising providing a patient with ulipristal acetate or a metabolite thereof, and informing the patient or a medical care worker that ulipristal acetate or a metabolite thereof affects activity of a cytochrome p450 isozyme, and that administration of ulipristal acetate or a metabolite thereof with a substance that affects activity of a cytochrome p450 isozyme can affect plasma concentration, safety, efficacy or any combination thereof of ulipristal acetate or a metabolite thereof, the substance, or both.05-10-2012
20100137235Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics - Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.06-03-2010
20100184714Compositions For Delivering A Drug - A composition comprises a mixture of a silicone and a first solvent, a drug, such as a hydrophilic or lipophilic pharmaceutical agent, a salt of a dialkyl sulfosuccinate, such as dioctyl sodium sulfosuccinate (DOSS), and a second solvent, such as an alcohol. The salt of a dialkyl sulfosuccinate solubilizes the drug. The composition can be topically applied to a substrate, such as skin, for delivering the drug. Drugs with a wide solubility range are soluble and compatible in the composition without separation or crystallization of the drugs occurring.07-22-2010
20120115803TREATMENT OF ACINETOBACTER WITH ALGINATE OLIGOMERS AND ANTIBIOTICS - The invention provides a method to improve the efficacy of an antibiotic to inhibit the growth of 05-10-2012
20120058963Macrolides with Anti-Inflammatory Activity - The present invention relates to novel semi-synthetic macrolides having anti-inflammatory activity. More particularly, the invention relates to 14- and 15-membered macrolides substituted at the 4″ position, to their pharmaceutically acceptable derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their activity and use in the treatment of inflammatory diseases and conditions in humans and animals, especially those diseases associated with excessive secretion of TNF-α, IL-1, IL-8, IL-2 or IL-5; and/or inhibitor of excessive lymphocyte proliferation; and/or excessive granulocyte degranulation.03-08-2012
20100227829MOTILIDE POLYMORPHS - The invention provides polymorphs of a motilide having a structure represented by formula Ia09-09-2010
20120071430SYNTHETIC ANALOGS OF BACTERIAL QUORUM SENSORS - Bacterial quorum-sensing molecule analogs having the following structures:03-22-2012
20120071429Novel antibacterial agents - Described herein are novel macrolides, the preparation of novel macrolides, the use of novel macrolides for preventing, treating, or ameliorating various conditions, and the use of novel macrolides as antibacterial agents.03-22-2012
20110065661PHARMACOPERONES FOR CORRECTING DISEASE STATES INVOLVING PROTEIN MISFOLDING - This application relates to methods of identifying pharmacoperone agents that can restore function to a misfolded protein, such as a misfolded protein that causes disease. Also disclosed are methods of using such pharmacoperone agents to treat a disease or disorder that results from the misfolded protein.03-17-2011
20100093650Pharmaceutical Anit-Infective Composition for Inhalation - A composition for inhalation, comprising at least: a) an effective amount of an antimicrobial aminoglycoside derivative or a salt thereof, and b) an effective amount of a biofilm modifier which is a macrolide derivative or a salt thereof.04-15-2010
20100173858COMPOSITIONS TO TREAT BACTERIAL AND INFLAMMATORY AFFECTIONS IN PET ANIMALS DOSAGE FORM AND METHOD TO TREAT PET ANIMALS - Compositions comprising at least one bactericidal antibiotic from the group of macrolides and a non-steroid anti-inflammatory with selective inhibiting activity for cycloxygenase 2 (COX-2). The present invention also refers to a dosage form of said compositions, as well as a method to treat pet animals, particularly dogs and cats. Compositions of the present invention are particularly useful for administration to provide animals with dosages of about 1.0 to 50 mg of compound A/kg of body weight of the animal and about 0.05 to 5.0 mg of compound B/kg of body weight of the animal, being compound A preferably azithromycin and compound B, meloxicam.07-08-2010
20100173859PHARMACEUTICAL FORMULATION FOR THE PRODUCTION OF RAPIDLY DISINTERGRATING TABLETS - Pharmaceutical formulation in the form of compacts comprising 07-08-2010
20100048498STABLE NON-DIHYDRATE AZITHROMYCIN ORAL SUSPENSIONS - This invention relates to a powder for oral suspension, and an oral suspension made there from, which comprises non-dihydrate azithromycin and an azithromycin conversion stabilizing excipient, wherein said excipient reduces the conversion of the form of azithromycin, when placed in suspension, to another form of azithromycin.02-25-2010
20080280841Amorphous Telithromycin Compound - The present invention relates to stable amorphous 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]erythromycin (telithromycin), methods for the preparation thereof, the use of stable amorphous telithromycin in the treatment of bacterial infections and to pharmaceutical compositions comprising stable amorphous telithromycin.11-13-2008
20100120707Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same - A dosage comprising an antibiotic, an estrogen, and a progestagen is provided. The dosage can be oral, or administered in other methods, such as intravaginally with a tampon. The dosage can be used for menstrual suppression, contraception, and/or hormone replacement therapy. A method of treating a patient with the dosage comprises administering the dosage to the patient over a course of treatment, in amounts or frequencies that can remain constant, or be varied.05-13-2010
20120083462Pharmaceutical anti-infective composition for inhalation - An anti-infective composition for inhalation, containing, at least an effective amount of an antimicrobial aminoglycoside compound or a salt thereof; and an effective amount of a biofilm modifier which is a macrolide compound or salt thereof.04-05-2012
20090018089CRYSTALLINE FORMS OF MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY - the present invention relates to macrolide compounds endowed with antiinflammatory activity and more particularly relates to new stable crystalline forms of a macrolide derivative with antiinflammatory activity, processes for the preparation of such forms, pharmaceutical compositions containing them as active ingredient and the use of said crystalline forms for the treatment of inflammatory diseases.01-15-2009
20120277174NEW MACROLIDES AND THEIR USE - The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.11-01-2012
20120329741NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF - Compounds of Formula I or II, and methods of making and using thereof, are described herein.12-27-2012
2010013723410-SUBSTITUTED MACROLIDE ANTIBIOTICS - Disclosed herein are 10-desmethyl, 10 substituted-macrolides, their preparation, pharmaceutical compositions containing them, their use and methods of treatment using them. The 10-desmethyl macrolides are particularly useful as antibiotics.06-03-2010
20090131343USE OF BRIDGED MACROLIDES OR TYLOSIN DERIVATIVES IN TREATING INFLAMMATORY BOWEL DISEASES - The invention provides methods utilizing bridged macrolide or tylosin derivatives for the treatment of patients with inflammatory bowel diseases. The methods of the invention provide for the administration to a patient of a therapeutically effective amount of a bridged macrolide or a tylosin derivative, pharmaceutically acceptable derivatives thereof, and combinations thereof for a period of time sufficient to obtain a desired alleviation of one or more symptoms of the inflammatory bowel disease.05-21-2009
20130018008CRYSTALLINE FORMS OF A MACROLIDE, AND USES THEREFOR - New crystalline forms of macrolide compounds, and pharmaceutical compositions thereof, are described herein. In addition, processes for preparing the crystalline forms are described herein.01-17-2013
20110160156Pharmaceutical Composition for the Eradication of Helicobacter Pylori and Preparation Method Thereof - The present invention relates to a pharmaceutical composition and its preparation method for the eradication of 06-30-2011
20080249035Polymorph of Clarithromycin (Form V) - A polymorphic form of clarithromycin (form V) which exhibits a characteristic X-ray diffraction pattern, a method for producing such polymorphic clarithromycin, and the use of such polymorphic clarithromycin to treat bacterial infections.10-09-2008
20080249033Carbamate Linked Macrolides Useful For The Treatment Of Microbial Infections - The present invention relates to 14- or 15-membered macrolides substituted at the 4″ position of formula (I)10-09-2008
200802277309A-Carbamoyl and Thiocarbamoyl Azalides With Antimalarial Activity - 9a-carbamoyl and thiocarbamoyl azalides A and their pharmaceutically acceptable derivatives are useful for treatment and prevention of malaria.09-18-2008
20130172280HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES - The invention described herein pertains to a novel macrolide antibacterial agent of formula (I): A-L-Q, as defined herein, and pharmaceutically acceptable salts, solvates, and hydrates thereof. Inter alia, the new macrolide antibacterial agent is active against a number of bacterial species, including resistant species.07-04-2013
20080221047Aminoakyl methacrylate copolymer E for maintaining solubility of poorly-soluble drug - A pharmaceutical composition comprising aminoalkyl methacrylate copolymer E, an acidic substance, and a poorly-soluble drug, wherein the aminoalkyl methacrylate copolymer E and the acidic substance are uniformly mixed, and solubility of the poorly-soluble drug is maintained for at least 30 minutes is disclosed.09-11-2008
20080221046Macrolides With Anti-Inflammatory Activity - The present invention relates to novel semi-synthetic macrolides having anti-inflammatory activity. More particularly, the invention relates to 14- and 15-membered macrolides substituted at the 4″ position, to their pharmaceutically acceptable derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their activity and use in the treatment of inflammatory diseases and conditions in humans and animals, especially those diseases associated with excessive secretion of TNF-α, IL-1, IL-8, IL-2 or IL-5; and/or inhibitor of excessive lymphocyte proliferation; and/or excessive granulocyte degranulation.09-11-2008
201000416186-11 Bridged Oxime Erythromycin Derivatives - The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof:02-18-2010
20130102551ANTIBIOTIC COMPOSITIONS - The invention relates to solid pharmaceutical or veterinary compositions comprising substantially pure Tulythromycin A in form of an addition salt with one or more acids, and to methods for preparing them. Following reconstitution with an aqueous solvent, the resulting solutions of Tulathromycin A may be administered to a mammal in order to treat bacterial or protozoal infections.04-25-2013
20130102550AMORPHOUS ROXITHROMYCIN COMPOSITION - This invention relates to a macrolide composition, more particularly an amorphous form (Form-III) of 3R, 4S, 5S, 6R, 7R, 9R, 11S, 12R, 13S, 14R-6-[(2S, 3R, 4S, 6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7, 12, 13-trihydroxy-4-[(2R, 4R, 5S, 6S)-5-hydroxy-4-methoxy-4, 6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxy-imino)-3, 5, 7, 9, 11, 13-hexamethyl-1-oxacyclotetradecan-2-one or roxithromycin characterised by the absence of peaks in the infra-red spectrum of amorphous (Form-III) of roxithromycin at 3577.15; 3526.03; 3465.27 and 3276.24 cm-1 relative to the infra-red spectrum of the prior art roxithromycin raw material displaying peaks at 3577.15; 3526.03; 3465.27 and 3276.24 cm-1 and further characterised by an increased solubility of at least 50% over prior art anhydrous and monohydrated roxithromycin in acetate buffer (pH 4.5), phosphate buffer (pH 6.8) and water.04-25-2013
20110218166MUCOADHERENTS COMPOSITIONS AND THEIR USE - The present invention has as its objective to provide mucoadherent compositions with enhanced properties of bioadhesivity, consistency, stability and vaginal pH regulation. It can also be the carrier of an active principle for the treatment or prophylaxis of disturbances or diseases caused in mucosa, particularly in the vaginal tract, as well as their use.09-08-2011
20080200404Novel Antimalarial 9A-Carbamoyl-Aminoalkyl and 9A-Thiocarbamoyl-Aminoalkyl Azalides - Novel 9a-N′-substituted-carbamoyl- and thiocarbamoyl-aminoalkyl-9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A and 3-O-decladinosyl-9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A compounds having antimalarial activity are claimed. More particularly, the invention relates to 9a-N′-substituted-carbamoyl- and thiocarbamoyl-β-aminoethyl- or -γ-aminopropyl-9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A and 3-O-decladinosyl-9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A compounds and to pharmaceutically acceptable derivatives thereof having antimalarial activity.08-21-2008
200802004039A-Carbamoyl and Thiocarbamoyl Azalides with Anti-Inflammatory Activity - The use of semi-synthetic 9a-carbamoyl or thiocarbamoyl azalides for the treatment and prevention of inflammatory diseases and conditions in humans and animals. More particularly, the invention relates to the use of 15-membered azalides having at the 9a-position carbamoyl or thiocarbamoyl group, and their pharmaceutically acceptable derivatives for the treatment and prevention of inflammatory diseases and conditions in humans and animals.08-21-2008
20110237534METHODS FOR TREATING GASTROINTESTINAL DISEASES - Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating gastrointestinal diseases.09-29-2011
20130150315Anti-Protozoal for Apicomplexan Protozoa - The invention comprising the heretofore veterinary anti-protozoal decoquinate and one or both of a redox drug or macrolide drug for prophylaxis or treatment of 06-13-2013
20080234211Decladinosyl-Macrolides With Anti-Inflammatory Activity - The present invention relates to novel semi-synthetic macrolides having anti-inflammatory activity. More particularly, the invention relates to 14- and 15-membered macrolides lacking cladinose sugar substituted at the C-3 position, to their pharmaceutically acceptable derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their activity and use in the treatment of inflammatory diseases and conditions in humans and animals, especially those diseases associated with excessive secretion of TNF-α, IL-1, IL-6, IL-8, IL-2 or IL-5; and/or inhibitor of excessive lymphocyte proliferation; and/or excessive granulocyte degranulation.09-25-2008
20130196939DETECTION OF DNA SEQUENCES AS RISK FACTORS FOR HIV INFECTION - A method for identifying a risk factor for diseases, disorders or conditions, such as those caused by human immunodeficiency virus, using the polymerase chain reaction and specific primers. Methods for treating patients having these diseases, disorders or conditions by antimicrobial treatment of the risk factor by combined antiviral and antibacterial treatment or by sustaining or stimulating the subject's immune system. Methods for screening biological products including red blood cell preparations. Primers and methods for detecting nucleic acids or microbial agents associated with red blood cells, such as those associated with red blood cells in subjects infected with HIV and undergoing antiretroviral therapy.08-01-2013

Patent applications in class The hetero ring has exactly 13 ring carbons (e.g., erythromycin, etc.)